

From: [Lee, Anthony](#)
To: [Rick Lyon](#); [Chris G](#); [Glenn P](#)
Cc: [Bittleman, Katelyn](#)
Subject: RE: [EXTERNAL] Rebotix Repair, LLC re Document Number CPT2000126
Date: Friday, July 22, 2022 7:20:23 AM
Attachments: [image001.png](#)

Dear Rebotix team,

In my prior communications below, specifically in my email dated Wednesday, April 06, 2022 5:58 AM in reference to CPT2000126, I used the term “decision” in a manner that may have incorrectly implied that FDA had made an official regulatory determination related to Rebotix, which Rebotix has now suggested it wants to “appeal.” To clarify, FDA conducted a preliminary **informal assessment** of the limited materials previously provided by Rebotix, and FDA has not conducted an official regulatory evaluation.

Informal communications with FDA staff do not represent the formal position of FDA and do not bind or otherwise obligate or commit the agency to the views expressed. This is why there is nothing for Rebotix to appeal at this time. For additional information on appeals that would be available once an official regulatory determination has issued, please see FDA guidance, “Center for Devices and Radiological Health (CDRH) Appeals Process” (<https://www.fda.gov/media/128444/download>).

If you wish to receive a regulatory evaluation of Rebotix’s materials, we encourage you to submit an application such as a 510(k).

Thank you for your time and willingness to participate in our recent interactions.

Best regards,
 Anthony Lee

Anthony Lee, PhD, MBA

Team Lead

Robotic Assisted Surgery Devices Team

Division of Health Technology 4A | OHT4: Surgical & Infection Control Devices

Office of Product Evaluation and Quality | Center for Devices and Radiological Health



Office: (240) 402-5935

E-mail: Anthony.Lee1@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the

EXHIBIT

204

exhibitstickers.com

customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1611&S=E>

THIS MESSAGE IS INTENDED FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by email or telephone found above.

From: Lee, Anthony

Sent: Friday, April 8, 2022 2:28 PM

To: Rick Lyon <rick@dovel.com>; Chris G <chris@rebotixrepair.com>

Cc: Bittleman, Katelyn <Katelyn.Bittleman@fda.hhs.gov>

Subject: RE: [EXTERNAL] Rebotix Repair, LLC re Document Number CPT2000126

Dear Rick and Chris,

Thank you for your time earlier today. As mentioned during our call, the Agency believes that the activities of Rebotix constitute remanufacturing and would require FDA review and clearance (e.g. 510(k) / de Novo). We therefore request that Rebotix stop engaging in the current activities until an application is reviewed and cleared/granted.

The instruments in question no longer maintain the same safety and effectiveness profile as cleared with the original manufacturer's own submission. During premarket review, FDA reviews test data to the labeled number of reuse cycles. This includes, but is not limited to, items such as electrical safety, reprocessing, software, and general performance testing. By extending the number of uses and modifying the instrument with a new chip, the prior information is no longer valid and requires additional review to the new labeled usage limit in order to establish safety and effectiveness. This is therefore different than returning the device to its original condition.

Please let us know if you have any further questions and what your intentions are for next steps.

Thank you again,
Anthony

Anthony Lee, PhD, MBA

Team Lead

Robotic Assisted Surgery Devices Team

Division of Health Technology 4A | OHT4: Surgical & Infection Control Devices

Office of Product Evaluation and Quality | Center for Devices and Radiological Health



Office: (240) 402-5935





Office: (240) 402-5935

E-mail: Anthony.Lee1@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1611&S=E>

THIS MESSAGE IS INTENDED FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by email or telephone found above.

From: Lee, Anthony

Sent: Monday, December 13, 2021 10:56 AM

To: Rick Lyon <rick@dovel.com>

Cc: Chris G <chris@rebotixrepair.com>

Subject: RE: [EXTERNAL] Rebotix Repair, LLC re Document Number CPT2000126

Good morning Rick,

We have discussed your request internally, and we are ok with extending the response by an additional 30 days. We look forward to hearing back from you in January.

Regards,
Anthony

Anthony Lee, PhD, MBA

Team Lead

Robotic Assisted Surgery Devices Team

Division of Health Technology 4A | OHT4: Surgical & Infection Control Devices

Office of Product Evaluation and Quality | Center for Devices and Radiological Health



Office: (240) 402-5935

E-mail: Anthony.Lee1@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1611&S=E>

THIS MESSAGE IS INTENDED FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by email or telephone found above.

From: Rick Lyon <rick@dovel.com>
Sent: Friday, December 10, 2021 11:51 AM
To: Lee, Anthony <Anthony.Lee1@fda.hhs.gov>
Cc: Chris G <chris@rebotixrepair.com>
Subject: [EXTERNAL] Rebotix Repair, LLC re Document Number CPT2000126

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Lee,

Thank you for taking the time to speak with me. Following up on our conversation, would it be possible to extend the deadline for our submission of the information you requested by 30 days? This would make the information due January 15, 2022, instead of next Thursday (December 16, 2021).

Best regards,
Rick Lyon
310-656-7066
Counsel for Rebotix Repair LLC